{
  "id": 19435465,
  "title": "Prime Medicine prices $125M stock offering at $3.50/share",
  "url": "https://urgent.news/2026/11/11/prime-medicine-prices-125m-stock-offering-at-3-50-share",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-11-11T02:44:34.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/company-news/prime-medicine-prices-125m-stock-offering-at-350share-93CH-5017543"
  },
  "original_language": "en",
  "account": "Cambridge, Massachusetts - Prime Medicine Inc. announced the pricing of a public offering for its common stock on Tuesday. The company sold 35.7 million shares at $3.50 per share, raising an estimated $125 million in gross proceeds before fees. Underwriters were given the option to purchase an additional 5.4 million shares over a 30-day period. The offering is set to close by November 12, 2026, pending usual closing conditions. Prime Medicine, a biotechnology firm, is utilizing its Prime Editing platform to develop therapies for liver, lung, immunology, and oncology conditions. The shares were issued pursuant to a shelf registration statement filed with the SEC on November 7, 2025, and became effective on March 4, 2026. Investment banks Jefferies, TD Cowen, and Goldman Sachs & Co. acted as the lead managers, with Oppenheimer & Co. and LifeSci Capital serving as passive managers.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}